Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient: A Case Report and Regional Literature Review
Abstract
Background: Pneumocystis jirovecii pneumonia (PJP) is a significant opportunistic infection in kidney transplant recipients, with a prevalence of ~1.28% in late-onset settings and mortality 10–50%. Despite TMP-SMX prophylaxis, PJP occurs with intensified immunosuppression, acute rejection, or CMV co-infection. Its nonspecific presentation delays diagnosis and worsens outcomes. Late-onset PJP is recognized. Case Presentation: A 29-year-old male kidney transplant recipient developed PJP eleven months post-transplantation from his HLA semi-identical mother. He presented with fever (39°C), exertional dyspnea, and oxygen saturation 85% on ambient air. Chest radiography showed bilateral alveolar-interstitial infiltrates; CT revealed diffuse ground-glass opacities with septal reticulations ("crazy-paving"). He received oxygen therapy, sulfamethoxazole (10 mg/kg for 28 days), and cefotaxime (15 days), with progressive improvement and stable graft function. Discussion: PJP occurring eleven months post-transplantation despite appropriate immunosuppression highlights challenges in prophylaxis duration and need for individualized risk stratification. Diagnosis relied on radiological findings; bronchoalveolar lavage with PCR remains the gold standard. The patient responded to TMP-SMX. CMV co-infection (26.9– 46.2% of PJP cases) is associated with increased severity and graft failure and was considered. TMP-SMX prophylaxis remains the cornerstone; optimal duration (3–12 months) is debated. The optimal duration of prophylaxis remains uncertain, with guidelines recommending 3 to 12 months depending on institutional protocols. Conclusion: PJP is frequent and potentially life-threatening in kidney transplant recipients. TMP-SMX prophylaxis should be systematic; early diagnosis and treatment are essential. Clinicians should maintain high suspicion and consider CMV co-infection. Research is needed to identify patients who may benefit from extended prophylaxis.